Altimmune (NASDAQ: ALT)
Altimmune Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Altimmune Company Info
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
News & Analysis
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Both competitors have promising lead programs, and enough cash, too.
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
The market for weight loss medicines keeps getting hotter and hotter.
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.